Retour
89
54
Fourchette du Jour
909,09 €
922,15 €
Fourchette 52 Semaines
623,78 €
1 133,95 €
Volume
1 603 428
Moyenne 50J / 200J
1 024,73 €
/
892,56 €
Clôture Précédente
903,02 €
Quick Summary
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 42,0 | 0,3 |
| P/B | 32,6 | 3,0 |
| ROE % | 101,4 | 3,7 |
| Net Margin % | 31,7 | 3,8 |
| Rev Growth 5Y % | 23,2 | 10,0 |
| D/E | 1,6 | 0,2 |
Objectif de Cours des Analystes
Hold
1 243,95 €
+35.7%
Low: 985,00 €
High: 1 350,00 €
P/E Prévisionnel
26,62
BPA Prévisionnel
34,43 €
Croissance BPA (est.)
+0,0%
CA Est.
81,69B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
60,97 €
56,29 € – 66,45 €
|
126,59B | 3 |
| FY2029 |
55,40 €
51,14 € – 60,38 €
|
117,17B | 3 |
| FY2028 |
49,21 €
42,81 € – 55,86 €
|
106,38B | 9 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-04 | 6,91 € | 7,54 € | +9,1% |
| 2025-10-30 | 5,69 € | 7,02 € | +23,4% |
| 2025-08-07 | 5,60 € | 6,31 € | +12,7% |
| 2025-05-01 | 3,26 € | 3,34 € | +2,5% |
| 2025-02-06 | 5,03 € | 5,32 € | +5,8% |
| 2024-10-30 | 1,47 € | 1,18 € | -19,7% |
| 2024-08-08 | 2,60 € | 3,92 € | +50,8% |
| 2024-04-30 | 2,46 € | 2,58 € | +4,9% |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 |
Fyrwald J Erik
Director
|
grant | 10 | 989,12 € | 9 891,20 € |
| Feb 17, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | 1 036,05 € | 5 180,25 € |
| Feb 16, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
other | 952 | — | — |
| Feb 9, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
grant | 4 163 | 1 044,67 € | 4 348 961,21 € |
| Feb 9, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
grant | 4 818 | 1 044,67 € | 5 033 220,06 € |
| Feb 9, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
grant | 1 196 | 1 044,67 € | 1 249 425,32 € |
| Feb 9, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
grant | 4 866 | 1 044,67 € | 5 083 364,22 € |
| Feb 9, 2026 |
Montarce Lucas
EVP & CFO
|
grant | 1 365 | 1 044,67 € | 1 425 974,55 € |
| Feb 9, 2026 |
Ricks David A
President, Chair, and CEO
|
grant | 38 914 | 1 044,67 € | 40 652 288,38 € |
| Feb 1, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
other | 9 612 | — | — |
| Feb 1, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
other | 10 125 | — | — |
| Feb 1, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
other | 8 300 | — | — |
| Jan 20, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | 1 041,29 € | 5 206,45 € |
| Dec 15, 2025 |
Fyrwald J Erik
Director
|
grant | 9 | 1 062,19 € | 9 559,71 € |
| Dec 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 14 | 1 062,19 € | 14 870,66 € |
| Nov 17, 2025 |
Kaelin William G Jr
Director
|
grant | 215 | 1 021,70 € | 219 665,50 € |
| Oct 20, 2025 |
Fyrwald J Erik
Director
|
grant | 12 | 808,96 € | 9 707,52 € |
| Sep 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 20 | 748,19 € | 14 963,80 € |
| Aug 12, 2025 |
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
|
buy | 1 000 | 634,41 € | 634 405,00 € |
| Aug 12, 2025 |
Sulzberger Gabrielle
Director
|
buy | 117 | 641,18 € | 75 018,29 € |
Dividend History
7 yr streakYield
0,01%
Payout Ratio
0,26%
Growth (3Y)
15,24%
Growth (5Y)
15,18%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Feb 13, 2026 | Mar 10, 2026 | 1,73 € | 0,60% |
| Nov 14, 2025 | Dec 10, 2025 | 1,50 € | 0,59% |
| Aug 15, 2025 | Sep 10, 2025 | 1,50 € | 0,83% |
| May 16, 2025 | Jun 10, 2025 | 1,50 € | 0,74% |
| Feb 14, 2025 | Mar 10, 2025 | 1,50 € | 0,64% |
| Nov 15, 2024 | Dec 10, 2024 | 1,30 € | 0,70% |
| Aug 15, 2024 | Sep 10, 2024 | 1,30 € | 0,54% |
| May 15, 2024 | Jun 10, 2024 | 1,30 € | 0,62% |
| Feb 14, 2024 | Mar 08, 2024 | 1,30 € | 0,62% |
| Nov 14, 2023 | Dec 08, 2023 | 1,13 € | 0,74% |
| Aug 14, 2023 | Sep 08, 2023 | 1,13 € | 0,81% |
| May 12, 2023 | Jun 09, 2023 | 1,13 € | 0,97% |
| Feb 14, 2023 | Mar 10, 2023 | 1,13 € | 1,17% |
| Nov 14, 2022 | Dec 09, 2022 | 0,98 € | 1,10% |
| Aug 12, 2022 | Sep 09, 2022 | 0,98 € | 1,23% |
| May 13, 2022 | Jun 10, 2022 | 0,98 € | 1,26% |
| Feb 14, 2022 | Mar 10, 2022 | 0,98 € | 1,50% |
| Nov 12, 2021 | Dec 10, 2021 | 0,85 € | 1,31% |
| Aug 12, 2021 | Sep 10, 2021 | 0,85 € | 1,25% |
| May 13, 2021 | Jun 10, 2021 | 0,85 € | 1,63% |
Points Clés
Revenue grew 23,17% annually over 5 years — strong growth
Earnings grew 94,88% over the past year
ROE of 101,35% indicates high profitability
Net margin of 31,66% shows strong profitability
Generating 8,97B in free cash flow
P/E of 41,95 — premium valuation
Croissance
Revenue Growth (5Y)
23,17%
Revenue (1Y)44,70%
Earnings (1Y)94,88%
FCF Growth (3Y)N/A
Qualité
Return on Equity
101,35%
ROIC32,26%
Net Margin31,66%
Op. Margin45,56%
Sécurité
Debt / Equity
1,60
Current Ratio1,58
Interest Coverage37,34
Valorisation
P/E Ratio
41,95
Forward P/E26,45
P/B Ratio32,63
EV/EBITDA30,35
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 44,70% | Revenue Growth (3Y) | 38,20% |
| Earnings Growth (1Y) | 94,88% | Earnings Growth (3Y) | 98,45% |
| Revenue Growth (5Y) | 23,17% | Earnings Growth (5Y) | 38,67% |
| Profitability | |||
| Revenue (TTM) | 65,18B | Net Income (TTM) | 20,64B |
| ROE | 101,35% | ROA | 18,35% |
| Gross Margin | 83,79% | Operating Margin | 45,56% |
| Net Margin | 31,66% | Free Cash Flow (TTM) | 8,97B |
| ROIC | 32,26% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,60 | Current Ratio | 1,58 |
| Interest Coverage | 37,34 | ||
| Dividends | |||
| Dividend Yield | 0,01% | Payout Ratio | 0,26% |
| Dividend Growth (3Y) | 15,24% | Dividend Growth (5Y) | 15,18% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 41,95 | Forward P/E | 26,45 |
| P/B Ratio | 32,63 | P/S Ratio | 13,28 |
| PEG Ratio | 0,49 | Forward PEG | N/A |
| EV/EBITDA | 30,35 | Fwd EV/EBITDA | 34,36 |
| Forward P/S | 10,60 | Fwd Earnings Yield | 3,78% |
| FCF Yield | 1,04% | ||
| Market Cap | 865,85B | Enterprise Value | 901,19B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65,18B | 45,04B | 34,12B | 28,54B | 28,32B |
| Net Income | 20,64B | 10,59B | 5,24B | 6,24B | 5,58B |
| EPS (Diluted) | 22,95 | 11,71 | 5,80 | 6,57 | 5,85 |
| Gross Profit | 54,62B | 36,62B | 27,04B | 21,91B | 21,01B |
| Operating Income | 29,70B | 17,50B | 10,79B | 8,65B | 7,93B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 112,48B | 78,71B | 64,01B | 49,49B | 48,81B |
| Total Liabilities | 85,94B | 64,44B | 53,14B | 38,71B | 39,65B |
| Shareholders' Equity | 26,54B | 14,19B | 10,77B | 10,65B | 8,98B |
| Total Debt | 42,50B | 33,64B | 25,23B | 16,24B | 16,88B |
| Cash & Equivalents | 7,16B | 3,27B | 2,82B | 2,07B | 3,82B |
| Current Assets | 55,63B | 32,74B | 25,73B | 18,03B | 18,45B |
| Current Liabilities | 35,23B | 28,38B | 27,29B | 17,14B | 15,05B |
Scores de Stratégies
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#13 of 157
Custom
Full Throttle
#44 of 146
Activité Récente
Entré
Growth Investing (Philip Fisher)
Mar 24, 2026
Entré
Full Throttle
Mar 24, 2026